Sunil Healthcare Closes Trading Window for FY26 Earnings Announcement

Sunil Healthcare Limited has closed its trading window for company insiders and their relatives, effective April 1, 2026. This restriction will remain in place until 48 hours after the company officially announces its audited financial results for the fourth quarter and the full fiscal year ending March 31, 2026.

This move is part of the company's adherence to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and its internal code of conduct. Such trading window closures are a standard corporate governance practice aimed at preventing insider trading. They ensure that individuals with access to non-public, price-sensitive information cannot trade the company's shares before this information is disclosed to the public, thereby promoting fair market practices and preventing unfair advantages.

Sunil Healthcare, established in 1976, manufactures hard gelatin and HPMC capsule shells for the pharmaceutical and food supplement industries, and also deals in ayurvedic medicines. The company has been publicly listed since January 2014 and operates a manufacturing facility in Alwar, Rajasthan. This practice of closing trading windows is common across many listed companies in India's stock market, including peers in the pharmaceutical and healthcare sector, as it is a regulatory requirement.

Consequently, designated persons within Sunil Healthcare and their immediate family members are now prohibited from buying or selling the company's shares during this period.

The company has not disclosed any specific risks associated with this trading window closure.

Investors will now focus on the upcoming announcement of Sunil Healthcare's audited financial results for FY26. The date of the board meeting where these results will be approved is anticipated by the market. Once the financial results are publicly declared, the trading window is expected to reopen 48 hours thereafter.